Evidence map›Paper›PMID 39751821›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.

Fatemeh Movahed, Ouldouz Navaei, Shiva Taghlidi, Maryam Nurzadeh, Maryam Eslami Gharaati, Maryam Rabiei

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Noncovalent Fluorescent Probe for Dynamic Monitoring of Hemoglobin Accumulation in Living Cells.Luminescence : the journal of biological and chemical luminescence · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatemeh MovahedDepartment of Gynecology and Obstetrics, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ouldouz NavaeiDepartment of Biotechnology, Università Milano-Bicocca Milano, Milan, Italy.
Shiva TaghlidiMedicine and Surgery, Università Degli Studi Di Milano-Bicocca, Milan, Italy.
Maryam NurzadehDepartment of Fetomaternal, Faculty of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. drnurzadeh@gmail.com.ORCID 0000-0001-9826-4992
Maryam Eslami GharaatiPhytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam RabieiObstetrics and Gynecology Department, Tehran University of Medical Sciences, Tehran, Iran. rabieimaryam1394@yahoo.com.ORCID 0000-0002-3484-8873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequent non-dermatologic malignancy in women. Breast cancer is characterized by the expression of the human epidermal growth factor receptor type 2 (HER2), and the presence or lack of estrogen receptor (ER) and progesterone receptor (PR) expression. HER2 overexpression is reported in about 20 to 25% of breast cancer patients, which is usually linked to cancer progression, metastases, and poor survival. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are the gold standards for determining HER2 status, even though IHC has largely focused on quantifying HER2

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesMolecular ImagingMolecular ProbesRadiopharmaceuticalsAnimalsFemaleHumansERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMolecular ProbesRadiopharmaceuticalsAffibodyAntibodyBreast cancerHER2Molecular imagingNanobody

Identifiers

PMID39751821

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.